Table 4 Correlation of adjusted dose of vedolizumab with its peak and trough levels.

From: The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease

Weight (kg)

BMI

Adjusted dose (mg/kg)

WK 2

WK 6

Peak level

Trough level

Peak level

Trough level

58.6

25.36

5.1

401.83

30.18

208.76

34.07

59.1

22.80

5.0

142.86

22

195.85

7.89

55.6

23.75

5.3

169.22

43.22

158.16

3.7

33.6

15.76

8.9

321.92

42.06

221.94

40.3

45.7

23.01

6.5

564.78

46.14

267.12

59.58

48.6

18.30

6.1

665.99

18.11

248.72

19.86

56.2

24.91

5.3

200.26

23.36

167.09

25.12

45

20.49

6.6

250

33.29

301.37

49.07

68.4

21.41

4.3

102.04

11.68

91.84

8.18

67.3

30.4S

4.4

112.24

7.59

141.58

7.79

63

16.13

4.7

181.12

39.14

213.01

13.43

84

23.18

3.5

117.35

12.58

125

15.19

63.9

19.63

4.9

164.54

16.49

62.5

8.76

60.3

23.148

4.9

62.5

8.67

44.93

4.09

75

21.66

4

164.54

14.6

102.04

16.36

62.6

24.52

4.7

89.29

5.84

60.16

7.59

Correlation of level and adjusted dose*

r = 0.71

p = 0.002

r = 0.70

p = 0.002

r = 0.69

p = 0.003

r = 0.49

p = 0.05

Correlation of level with BMI*

r = − 0.30

p = 0.24

r = − 0.31 p = 0.24

r = − 0.32

p = 0.22

r = − 0.30

p = 0.25

Correlation of level with weight*

r = − 0.56

p = 0.02

r = − 0.60 p = 0.01

r = − 0.57

p = 0.02

r = − 0.33

p = 0.20

  1. r Spearman correlation coefficient.
  2. *Type of statistical test.